Articles published by Blue Lake Biotechnology, Inc.

Blue Lake Biotechnology to Resume Enrollment of RSV-negative Toddlers in Phase 1/2a Clinical Trial of BLB201

November 21, 2025

From Blue Lake Biotechnology, Inc.

Via Business Wire

Blue Lake and CyanVac Publish Full Data from Open Label Phase 1 Clinical Study of COVID-19 Vaccine Candidate

July 07, 2025

From Blue Lake Biotechnology, Inc.

Via Business Wire

Blue Lake Biotechnology to Present Safety and Immunogenicity Data for its RSV Intranasal Vaccine Candidate at the 13th International RSV Symposium

March 10, 2025

From Blue Lake Biotechnology, Inc.

Via Business Wire

Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201

December 12, 2024

From Blue Lake Biotechnology, Inc.

Via Business Wire

Blue Lake and CyanVac Report Positive Phase 2a Data for Intranasal COVID-19 Vaccine Candidate

November 25, 2024

From Blue Lake Biotechnology, Inc.

Via Business Wire

Blue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress

October 21, 2024

From Blue Lake Biotechnology, Inc.

Via Business Wire

Blue Lake Biotechnology Reports Positive Interim Clinical Data in Children for Its RSV Vaccine Candidate

March 21, 2024

From Blue Lake Biotechnology, Inc.

Via Business Wire

Positive Phase 1 Data for Blue Lake Biotechnology’s Intranasal RSV Vaccine Published in Science Advances

October 25, 2023

From Blue Lake Biotechnology, Inc.

Via Business Wire

Blue Lake Biotechnology Presenting at Upcoming BioFuture and BIO Investor Forum Conferences

September 27, 2023

From Blue Lake Biotechnology, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.